Novartis Agrees To Stricter Safety Measures For MS Drug
Novartis AG will revise the safety guidelines for multiple sclerosis drug Gilenya following discussions with U.S. and European regulators prompted by sudden deaths of patients using the medicine, the firm announced...To view the full article, register now.
Already a subscriber? Click here to view full article